<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="119520">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02139670</url>
  </required_header>
  <id_info>
    <org_study_id>thrombin generation- pregnancy</org_study_id>
    <nct_id>NCT02139670</nct_id>
  </id_info>
  <brief_title>Thrombin Generation and Gestational Outcome</brief_title>
  <official_title>Thrombin Generation and Gestational Outcome in Women With Recurrent Pregnancy Loss</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HaEmek Medical Center, Israel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HaEmek Medical Center, Israel</source>
  <oversight_info>
    <authority>Israel: Ethics Commission</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In total 120 pregnant women's with history of recurrent miscarriages, are planned for
      inclusion in this trial. After signing an informed consent a blood sample will be obtained
      from each participant. The investigators will measure the thrombin generation  in plasma
      assessed by the calibrated automated thrombogram (CAT). The relation between pregnancy
      outcome and thrombin measurements will be determined
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <target_duration>9 Months</target_duration>
  <primary_outcome>
    <measure>pregnancy outcome</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Thrombophilia</condition>
  <arm_group>
    <arm_group_label>pregnant womens</arm_group_label>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      4 cc of serum will be retain until all blood samples will be collected
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        pregnant women with recurrent miscarriages undergoing investigation for Thrombophilia .
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt; 18

          -  signed inform consent

          -  first trimester

          -  two early miscarriages(before week 10) or one later abortions (after week 10)

        Exclusion Criteria:

          -  Chronic treatment with aspirin or other anticoagulants
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>mazen elias, prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>HaEmek Medical Center, Israel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>mazen elias, prof</last_name>
    <phone>972-4-6495139</phone>
    <email>elias_m@clalit.org.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Haemek medical center</name>
      <address>
        <city>Afula</city>
        <zip>18101</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mazen Elias, prof</last_name>
      <phone>972-4-6495139</phone>
      <email>elias_m@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Mazen Elias, prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>May 13, 2014</lastchanged_date>
  <firstreceived_date>August 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>HaEmek Medical Center, Israel</investigator_affiliation>
    <investigator_full_name>Elias mazen</investigator_full_name>
    <investigator_title>Director of Internal medicine</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Thrombophilia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
